СОВРЕМЕННЫЕ ВЗГЛЯДЫ НА ВОПРОСЫ ПАТОГЕНЕТИЧЕСКОЙ ТЕРАПИИ РЕВМАТОИДНОГО АРТРИТА

Авторы

  • D. G. Rekalov Zaporozhye State Medical University
  • A. V. Kulynych Zaporozhye State Medical University
  • S. I. Svistun Zaporozhye State Medical University
  • E. V. Presnyakova UE “Zaporizhzhia Regional Clinical Hospital” ZRC

DOI:

https://doi.org/10.14739/2310-1210.2013.6.20832

Ключевые слова:

ранний ревматоидный артрит, цитокины, биологические агенты, базисная болезнь-модифицирующая антиревматическая терапия

Аннотация

Приведены новые данные по вопросам лечения раннего ревматоидного артрита, а также короткий обзор международных исследований, посвященных вопросам современных методов базисной болезнь-модифицирующей антиревматической терапии. Представлены возможности выбора современного метода лечения раннего ревматоидного артрита. Показан значительный прогресс в патогенетических аспектах терапии, связанных с внедрением в ревматологическую практику биологических агентов, способных кардинально поменять прогноз ревматоидного артрита.

Библиографические ссылки

American College of Rheumatology Ad Hoc Committee on

Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis // Arthritis Rheum. – 1996. –Vol. 39. – P. 723–731.

American College of Rheumatology Ad Hoc Committee on

Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis: 2001 update // Arthritis Rheum. – 2001. – Vol. 44. – P. 1496–1503.

Aletaha D. 2010 Rheumatoid Arthritis Classifi cation Criteria An American College of Rheumatology / European League Against Rheumatism Collaborative Initiative / D. Aletaha, T. Neogi, A.J. Silman et al. // Arthritis and Rheumatism. –2010. – Vol. 62. – № 9. – P. 2569–2581.

Boers M. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis / M. Boers, A.C. Verhoeven, H.M. Markusse et al. // Lancet. – 1997. –Vol. 350. – P. 309–318.

Вrooks P.J. Birch-more DA. Pharmacokinetics of methotrexate

administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis / P.J. Brooks, W.J. Spruill, R.C. Parish // Arthritis Rheum. – 1990. – Vol. 33. – P. 91–94.

Cohen S.B. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary effi cacy and safety at twenty-four weeks REFLEX Trial Group / S.B. Cohen, P. Emery, M. Greenwald et al. // Arthritis Rheum. – 2006. – Vol. 54 (9). – Р. 2793–2806.

Chan F.K.L. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis / F.K.L. Chan, L.C.T. Hung, BY. Suen et al. // N Engl J Med. – 2002. – Vol. 347. – P. 2104–2110.

Choi H.K. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study / H.K. Choi, M.A. Hern, J.D. Seeger, J.M. Robins, F. Wolfe // Lancet. – 2002. – Vol. 359. – P. 1173–1177.

Choi H.K. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis / H.K. Choi, J.D. Seeger, K.M. Kuntz // J Rheumatol. – 2002. – Vol. 29. – P. 1156–1665.

Edwards J.C.W. Effi cacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis / J.C.W. Edwards, L. Szczepa´nski, J. Szechinski et al. // N Engl J Med. – 2004. – Vol. 350. – P. 2572–2581.

Edwards J.C.W. Effi cacy and safety of rituximab, a B-cell targeted chimeric monoclonal anti-body: a randomized, placebo-controlled trial in patients with rheumatoid arthritis / J.C.W. Edwards, L. Szczepanski, J. Szechinski et al. // Arthritis Rheum. – 2002. – Vol. 46. – Suppl: S197.

FitzGerald G.A. The coxibs, selective inhibitors of cyclooxygenase-2 / G.A. FitzGerald, C. Patrono // N Engl J Med. – 2001. – Vol. 345. – P. 433–442.

Furst D.E. Increasing methotrexate effect with increasing dose

in the treatment of resistant rheumatoid arthritis/ D.E. Furst,

R. Koehnke, L.F. Burmeister, J. Kohler, I. Cargill // J Rheumatol. – 1989. – Vol. 16. – P. 313–320.

Gabriel S. The epidemiology of rheumatoid arthritis / S. Gabriel // Rheum Dis Clin North Am. – 2001. – Vol. 27. – P. 269–281.

Genovese M. High dose oral methotrexate (MTX) in early RA is

needed for maximum effi cacy / M. Genovese, EC. Keystone, JRP. Tesser, BK. Finck, GT. Spencer-Green // Arthritis Rheum. – 2000. – Vol. 43. – Suppl: S382. Abstract.

Goldbach-Mansky R. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset / R. Goldbach-Mansky, J. Lee, A. McCoy et al. // Arthritis Res. – 2000. – Vol. 2. – P. 236–243.

Herman R.A. Pharmacokinetics of low-dose methotrexate in

rheumatoid arthritis patients / R.A. Herman, P. Veng Pedersen, J. Hoffman, R. Koehnke et al. // J Pharm Sci. – 1989. – Vol. 78. – P. 165–171.

Janssen N.M. The effects of immunosuppressive and antiinfl

ammatory medications on fertility, pregnancy, and lactation /

N.M. Janssen, M.S. Genta // Arch Intern Med. – 2000. – Vol. 160. – P. 610–619.

Kirwan J.R. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis / J.R. Kirwan // N Engl J Med. – 1995. – Vol. 333. – Р. 142–146.

Krishnan E. Reduction in long term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients / E. Krishnan, J.F. Fries // Am J Med. – 2003. – Vol. 115. – Р. 371–376.

Lipsky P.E. Infliximab and methotrexate in the treatment of rheumatoid arthritis / P.E. Lipsky, D.M.F.M. van der Heijde, E.W. St Clair et al. // N Engl J Med. – 2000. – 343. – P. 1594–1602.

Maini R. Therapeutic effi cacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis / R. Maini, F. Breedveld, J. Kalden et al. // Arthr. Rheum. – 1998. – Vol. 41. – P. 1552–1563.

Marmor M.F. Recommendations on screening for chloroquine

and hydroxychloroquine retinopathy: a report by the American

Academy of Ophthalmology / M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo, W.F. Mieler // Ophthalmology. – 2002. – Vol. 109. – P. 1377–1382

McDougall R. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls / R. McDougall, J. Sibley, M. Haga, A. Russell // J Rheumatol. – 1994. – Vol. 21. – P. 1207–1213.

Mclinnes IB. Rheumatoid arthritis: from bench to bedside /

IB. Mclinnes // Rheum Dis Clin North Am. – 2001. – Vol. 27. – P. 373–387.

Mikuls T.R. The changing face of rheumatoid arthritis therapy:

results of serial surveys / T.R. Mikuls, J. O’Dell // Arthritis Rheum. – 2000. – Vol. 43. – P. 464–465.

Moreland L.W. Glucocorticoids and rheumatoid arthritis: back

to the future? / L.W. Moreland, J.R. O’Dell // Arthritis Rheum. –

– Vol. 46. – P. 2553–2563.

Morgan S.L. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial / S.L. Morgan, J.E. Baggott, W.H. Vaughn et al. // Ann Intern Med. – 1994. – Vol. 121. – P. 833–841.

O’Dell J.R. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications / J.R. O’Dell, C.E. Haire, N. Erikson et al. // N Engl J Med. – 1996. – Vol. 334. – P. 1287–1291.

O’Dell J.R. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial / J.R. O’Dell,

Leff, G. Paulsen et al. // Arthritis Rheum. – 2002. – Vol. 46.

– P. 1164–1170.

O’Dell J.R. Treating rheumatoid arthritis early: a window of

opportunity / J.R. O’Dell // Arthritis Rheum. – 2002. – Vol. 46.

– P. 283–285.

Olsen N.J. New drugs for rheumatoid arthritis / N.J. Olsen,

C.M. Stein // N Engl J Med. – 2004. –Vol. 350. – P. 2167–2179.

Ortendahl M. The methotrexate therapeutic response in rheumatoid arthritis / M. Ortendahl, T. Holmes, JD. Schettler, JF. Fries // J Rheumatol. – 2002. – Vol. 29. –P. 2084–2091.

Pincus T. Long-term drug therapy for rheumatoid arthritis in

seven rheumatology private practices. II. Second line drugs and prednisone / T. Pincus, S.B. Marcum, L.F. Callahan // J Rheumatol. – 1992. – Vol. 19. – P. 1885–1894.

Quinn M.A. The therapeutic approach of early intervention

for rheumatoid arthritis: what is the evidence? / M.A. Quinn,

P.G. Conaghan, P. Emery // Rheumatology (Oxford). – 2001. – Vol. 40. – P. 1211–1220.

Rau R. Comparison of intramuscular methotrexate and gold

sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients / R. Rau, G. Herborn, H. Menninger, J. Blechschmidt // Br J Rheumatol. – 1997. – Vol. 36. – P. 345–352.

Saag K.G. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events / K.G. Saag, R. Koehnke, J.R. Caldwell et al. // Am J Med. – 1994. – Vol. 96. – P. 115–123.

Saag KG. Low-dose corticosteroids in rheumatoid arthritis: a

meta-analysis of their moderate term effectiveness / K.G. Saag, L. Criswell, K.M. Sems, M.D. Nettleman, S. Kolluri // Arthritis Rheum. – 1996. – Vol. 39. – P. 1818–1825.

Silverstein F. E. Gastrointestinal toxicity with celecoxib vs non

steroidal anti-infl ammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial / F.E. Silverstein, G. Faich, J.L. Goldstein et al. // JAMA. – 2000. – Vol. 284. – P. 1247–1255.

Smolen J.S. Effi cacy and safety of lefl unomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a doubleblind, randomised, multicentre trial / J.S. Smolen, J.R. Kalden, D.L. Scott et al // Lancet. – 1999. – Vol. 353. – P. 259–266.

Sokka T. Eligibility of patients in routine care for major clinical

trials of anti-tumor necrosis factor alpha agents in rheumatoid

arthritis / T. Sokka, T. Pincus // Arthritis Rheum. – 2003. – Vol. 48. – P. 313–318.

Strand V. Treatment of active rheumatoid arthritis with lefl unomide compared with placebo and methotrexate / V. Strand, S. Cohen, M. Schiff et al. // Arch Intern Med. – 1999. – Vol. 159. – P. 2542–5250.

Strand V. The risk of cardiovascular thrombotic events with

selective cyclooxygenase2 inhibitors / V. Strand, M. Hochberg // Arthritis Rheum. – 2002. – Vol. 47. – P. 349–355.

Tugwell P. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis / P. Tugwell, T. Pincus // N Engl J Med. – 1995. – Vol. 333. – P. 137–141.

Van der Heijde D.M. Joint erosions and patients with early rheumatoid arthritis / D.M. van der Heijde // Br J Rheumatol. – 1995. – Vol. 34. – Suppl 2. – Р. 74–78.

Van Ede A.E. Effect of folic or folinic acid supplementation on

the toxicity and effi cacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, doubleblind, placebo controlled study / A.E. van Ede, R.F. Laan, M.J. Rood et al. // Arthritis Rheum. – 2001. – Vol. 44. – P. 1515–1524.

Weinblatt M.E. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate / M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst et al. // N Engl J Med. – 1999. – Vol. 340. – P. 253–259.

GaIB online. Sandoz announces biosimilar rituximab [Електронний ресурс]. – Режим доступу: http://www.gabionline. net/Biosimilars/News/Sandoz-announces-biosimilar-rituximab (accessed 8 Nov 2012).

ClinicalTrials.gov. GP2013 in the Treatment of RA Patients

Refractory to or Intolerant of Standard Therapy [Електронний

ресурс]. – Режим доступу: http://www.clinicaltrials.gov/ (accessed 8 Nov 2012).

ClinicalTrials.gov. Effi cacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis [Електронний

ресурс]. – Режим доступу: http: //www.clinicaltrials.gov/ct2/

show/NCT01682512?term=BI (accessed 8 Nov 2012).

Загрузки

Выпуск

Раздел

Обзоры